niacinamide has been researched along with Adenocarcinoma, Papillary in 2 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Adenocarcinoma, Papillary: An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marquez, CB | 1 |
| Smithberger, EE | 1 |
| Bair, SM | 1 |
| Wenham, RM | 1 |
| Fenske, NA | 1 |
| Glass, LF | 1 |
| Cherpelis, BS | 1 |
| Kloos, RT | 1 |
| Ringel, MD | 1 |
| Knopp, MV | 1 |
| Hall, NC | 1 |
| King, M | 1 |
| Stevens, R | 1 |
| Liang, J | 1 |
| Wakely, PE | 1 |
| Vasko, VV | 1 |
| Saji, M | 1 |
| Rittenberry, J | 1 |
| Wei, L | 1 |
| Arbogast, D | 1 |
| Collamore, M | 1 |
| Wright, JJ | 1 |
| Grever, M | 1 |
| Shah, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of BRAFV600E Intratumor Heterogeneity on the Efficacy of Tyrosine Kinase Inhibitors in the Treatment of Radioiodine-resistant Thyroid Cancer[NCT01700699] | 50 participants (Anticipated) | Observational | 2012-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for niacinamide and Adenocarcinoma, Papillary
| Article | Year |
|---|---|
Phase II trial of sorafenib in metastatic thyroid cancer.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; | 2009 |
1 other study available for niacinamide and Adenocarcinoma, Papillary
| Article | Year |
|---|---|
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined C | 2009 |